On the basis of the existing literature and the clinical experience, the members of the panel agree that the inodilator levosimendan offers potential benefits in treatment of acute heart failure and/or cardiogenic shock complicating acute coronary syndrome due to a range of distinct effects including positive inotropy, restauration of ventriculo-arterial coupling, increases in tissueperfusion,and anti-stunning and anti-inflammatory effects. Levosimendan can be used alone or in combination with other agents, but it requires continuous monitoring due to the risk of hypotension.
The panel agrees on the practical recommendations on indication, dosing, and monitoring.